Skip to content

10x Genomics

US · TXG #1311 by market cap Listed 2019
51.80 -5.58 -9.72%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 61 in the most recent period (2026/Q3).
  • Total institutional ownership rose 4.4 percentage points.

Ownership vs. money flow

Aligned

Institutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
101.51% +4.44pp
Institutions
525 +61
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund82.30%
Hedge Fund9.04%
Individual/Insider7.72%
Public Company6.10%
VC/PE Fund1.36%
Government Pension Fund0.71%
Family Office/Trust0.66%
Private Company0.66%
Insurance Company0.46%

Top holders as of 2026-09-30

FMR 14.47% · 19.03M sh
T. Rowe Price Group, Inc. 11.64% · 15.31M sh
BlackRock 8.80% · 11.57M sh
ARK Investment Management LLC 4.77% · 6.27M sh
Vanguard Portfolio Management, LLC 4.50% · 5.91M sh
Quantinno Capital Management LP 4.16% · 5.48M sh
Vanguard Capital Management, LLC 4.10% · 5.39M sh
Serge Saxonov 3.13% · 4.11M sh
Amova Asset Management 3.22% · 4.19M sh
Benjamin Hindson 2.53% · 3.32M sh
Morgan Stanley 2.49% · 3.27M sh
Geode Capital Management, LLC 2.37% · 3.08M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 11 buys · 38 sells

NameRoleStake
Serge Saxonov Chief Executive Officer 3.13%
Benjamin Hindson Co-Founder, President, Chief Scientific Officer & Director 2.53%
John Stuelpnagel Independent Chairperson 1.85%
Adam Taich CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer 0.08%
Alan Mateo Independent Director 0.05%
Sridhar Kosaraju Independent Director 0.05%
Kimberly Popovits Independent Director 0.02%
Shehnaaz Suliman Independent Director 0.01%
Sarah Teichmann -- 0.01%
Joseph Gilliam Director 0.00%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-09 Serge Saxonov Chief Executive Officer Open Market Disposition -31,000 $62.90
2026-10-27 Joseph Gilliam Director Initial Statement of Beneficial 0 --
2026-09-21 Shehnaaz Suliman Independent Director Automatic Disposition -5,723 $78.20–82.28
2026-09-21 Serge Saxonov Chief Executive Officer Automatic Disposition -25,000 $78.23–82.37
2026-09-08 Adam Taich CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer Automatic Disposition -46,388 $63.68–65.26
2026-09-02 John Stuelpnagel Independent Chairperson Open Market Disposition -20,000 $60.66–62.61
2026-08-31 Serge Saxonov Chief Executive Officer Other Disposition -100 --
2026-08-25 Serge Saxonov Chief Executive Officer Automatic Disposition -10,486 $63.02–64.75
2026-08-23 Shehnaaz Suliman Independent Director Automatic Disposition -2,207 $62.73–63.97
2026-08-23 Adam Taich CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer Open Market Disposition -17,166 $63.02
2026-08-23 Serge Saxonov Chief Executive Officer Open Market Disposition -18,545 $63.02
2026-08-23 Benjamin Hindson Co-Founder, President, Chief Scientific Officer & Director Open Market Disposition -13,818 $63.02
2026-08-19 Serge Saxonov Chief Executive Officer Other Disposition -4,000 --
2026-08-13 Sarah Teichmann -- Automatic Disposition -7,551 $57.15–57.29
2026-08-13 Sarah Teichmann -- Intent to Sell (Form 144) -2,273 $57.15
2026-08-12 Sarah Teichmann -- Intent to Sell (Form 144) -5,278 $57.29
2026-08-10 John Stuelpnagel Independent Chairperson Open Market Disposition -20,000 $57.58–58.73
2026-06-21 Serge Saxonov Chief Executive Officer Automatic Disposition -30,000 $33.29–36.16
2026-06-15 Shehnaaz Suliman Independent Director Automatic Disposition -5,723 $32.59–33.27
2026-06-03 Kimberly Popovits Independent Director Other Acquisition +8,829 --

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:38 · For reference only, not investment advice and not tailored to your situation.

10x Genomics discussion 0 comments

Add a comment